Literature DB >> 26700070

Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity.

Valentina Medici1, Stephen A McClave2, Keith R Miller3.   

Abstract

Obesity is one of the most common chronic conditions in the world. Its management is difficult, partly due to the multiple associated comorbidities including fatty liver, diabetes, hypertension, and hyperlipidemia. As a result, the choice of prescription medications in overweight and obese patients has important implications as some of them can actually worsen the fat accumulation and its associated metabolic complications. Several prescription medications are associated with weight gain with mechanisms that are often poorly understood and under-recognized. Even less data are available on the distribution of fat and lipotoxicity (the organ damage related to fat accumulation). The present review will discuss the drugs associated with weight gain, their mechanism of action, and the magnitude and timing of their effect.

Entities:  

Keywords:  Lipotoxicity; Medications; Obesity; Side effects; Weight

Mesh:

Substances:

Year:  2016        PMID: 26700070     DOI: 10.1007/s11894-015-0479-4

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  136 in total

1.  Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review.

Authors:  K N Roy Chengappa; L Chalasani; Jaspreet S Brar; H Parepally; Patricia Houck; Joseph Levine
Journal:  Clin Ther       Date:  2002-10       Impact factor: 3.393

2.  Changes in weight during a 1-year trial of fluoxetine.

Authors:  D Michelson; J D Amsterdam; F M Quitkin; F W Reimherr; J F Rosenbaum; J Zajecka; K L Sundell; Y Kim; C M Beasley
Journal:  Am J Psychiatry       Date:  1999-08       Impact factor: 18.112

3.  Weight and body composition changes during oral contraceptive use in obese and normal weight women.

Authors:  Elizabeth R Mayeda; Anupama H Torgal; Carolyn L Westhoff
Journal:  J Womens Health (Larchmt)       Date:  2013-10-24       Impact factor: 2.681

Review 4.  Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis.

Authors:  Juan Pablo Domecq; Gabriela Prutsky; Aaron Leppin; M Bassam Sonbol; Osama Altayar; Chaitanya Undavalli; Zhen Wang; Tarig Elraiyah; Juan Pablo Brito; Karen F Mauck; Mohammed H Lababidi; Larry J Prokop; Noor Asi; Justin Wei; Salman Fidahussein; Victor M Montori; Mohammad Hassan Murad
Journal:  J Clin Endocrinol Metab       Date:  2015-01-15       Impact factor: 5.958

5.  Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver.

Authors:  Emilie Lauressergues; Françoise Martin; Audrey Helleboid; Emmanuel Bouchaert; Didier Cussac; Régis Bordet; Dean Hum; Gérald Luc; Zouher Majd; Bart Staels; Patrick Duriez
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-02-19       Impact factor: 3.000

6.  Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

Authors:  V Fonseca; J Rosenstock; R Patwardhan; A Salzman
Journal:  JAMA       Date:  2000-04-05       Impact factor: 56.272

7.  The effect of angiotensin-converting enzyme inhibition using captopril on energy balance and glucose homeostasis.

Authors:  Annette D de Kloet; Eric G Krause; Dong-Hoon Kim; Randall R Sakai; Randy J Seeley; Stephen C Woods
Journal:  Endocrinology       Date:  2009-06-04       Impact factor: 4.736

8.  Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis.

Authors:  Peter K Wung; Troy Anderson; Kevin R Fontaine; Gary S Hoffman; Ulrich Specks; Peter A Merkel; Robert Spiera; John C Davis; E William St Clair; W Joseph McCune; John H Stone
Journal:  Arthritis Rheum       Date:  2008-05-15

9.  Body weight changes with beta-blocker use: results from GEMINI.

Authors:  Franz H Messerli; David S H Bell; Vivian Fonseca; Richard E Katholi; Janet B McGill; Robert A Phillips; Philip Raskin; Jackson T Wright; Sripal Bangalore; Fred K Holdbrook; Mary Ann Lukas; Karen M Anderson; George L Bakris
Journal:  Am J Med       Date:  2007-07       Impact factor: 4.965

10.  Antihypertensive medication classes used among medicare beneficiaries initiating treatment in 2007-2010.

Authors:  Shia T Kent; Daichi Shimbo; Lei Huang; Keith M Diaz; Meredith L Kilgore; Suzanne Oparil; Paul Muntner
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

View more
  8 in total

Review 1.  Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function-Mechanisms and Possible Therapeutic or Preventive Measures: an Update.

Authors:  Ann A Verhaegen; Luc F Van Gaal
Journal:  Curr Obes Rep       Date:  2021-01-05

Review 2.  Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options.

Authors:  A A Verhaegen; L F Van Gaal
Journal:  J Endocrinol Invest       Date:  2017-06-28       Impact factor: 4.256

Review 3.  Obesity II: Establishing causal links between chemical exposures and obesity.

Authors:  Jerrold J Heindel; Sarah Howard; Keren Agay-Shay; Juan P Arrebola; Karine Audouze; Patrick J Babin; Robert Barouki; Amita Bansal; Etienne Blanc; Matthew C Cave; Saurabh Chatterjee; Nicolas Chevalier; Mahua Choudhury; David Collier; Lisa Connolly; Xavier Coumoul; Gabriella Garruti; Michael Gilbertson; Lori A Hoepner; Alison C Holloway; George Howell; Christopher D Kassotis; Mathew K Kay; Min Ji Kim; Dominique Lagadic-Gossmann; Sophie Langouet; Antoine Legrand; Zhuorui Li; Helene Le Mentec; Lars Lind; P Monica Lind; Robert H Lustig; Corinne Martin-Chouly; Vesna Munic Kos; Normand Podechard; Troy A Roepke; Robert M Sargis; Anne Starling; Craig R Tomlinson; Charbel Touma; Jan Vondracek; Frederick Vom Saal; Bruce Blumberg
Journal:  Biochem Pharmacol       Date:  2022-04-05       Impact factor: 6.100

4.  Visceral Fat Dysfunctions in the Rat Social Isolation Model of Psychosis.

Authors:  Stefania Schiavone; Giulia M Camerino; Emanuela Mhillaj; Margherita Zotti; Marilena Colaianna; Angelo De Giorgi; Antonello Trotta; Francesco P Cantatore; Elena Conte; Maria Bove; Paolo Tucci; Maria G Morgese; Luigia Trabace
Journal:  Front Pharmacol       Date:  2017-11-08       Impact factor: 5.810

5.  Serotonin Transporter Deficiency is Associated with Dysbiosis and Changes in Metabolic Function of the Mouse Intestinal Microbiome.

Authors:  Megha Singhal; Benjamin A Turturice; Christopher R Manzella; Ravi Ranjan; Ahmed A Metwally; Juliana Theorell; Yue Huang; Waddah A Alrefai; Pradeep K Dudeja; Patricia W Finn; David L Perkins; Ravinder K Gill
Journal:  Sci Rep       Date:  2019-02-14       Impact factor: 4.996

6.  What is the prevalence, and what are the clinical correlates, of insulin resistance in young people presenting for mental health care? A cross-sectional study.

Authors:  Elizabeth M Scott; Joanne S Carpenter; Frank Iorfino; Shane P M Cross; Daniel F Hermens; Jeanne Gehue; Chloe Wilson; Django White; Sharon L Naismith; Adam J Guastella; Ian B Hickie
Journal:  BMJ Open       Date:  2019-05-27       Impact factor: 2.692

Review 7.  A comprehensive diagnostic approach to detect underlying causes of obesity in adults.

Authors:  Eline S van der Valk; Erica L T van den Akker; Mesut Savas; Lotte Kleinendorst; Jenny A Visser; Mieke M Van Haelst; Arya M Sharma; Elisabeth F C van Rossum
Journal:  Obes Rev       Date:  2019-03-01       Impact factor: 9.213

8.  Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice.

Authors:  Geng-Ruei Chang; Po-Hsun Hou; Wei-Cheng Yang; Chao-Min Wang; Pei-Shan Fan; Huei-Jyuan Liao; To-Pang Chen
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.